PFG
CTIC

Piershale Financial Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Piershale Financial Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-19
Closed -$1K – 217
2014
Q1 		$1K Buy
+19
New +$649 ﹤0.01% 137

Other funds holding CTIC

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Piershale Financial Group's CTIC Position: Q2 2014 in Review

Piershale Financial Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2014, closing a stake of 19 shares — an estimated $1K sold.

Piershale Financial Group first reported a position in CTIC in Q1 2014 and held it in 1 quarter. The position peaked at $1K in Q1 2014. 89 funds tracked by Wall St. Rank hold CTIC as of Q2 2014.

  • Piershale Financial Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2014 after selling out during the quarter.
  • Piershale Financial Group sold 19 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2014, an estimated $1K.
  • Piershale Financial Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 1 quarter.
  • Piershale Financial Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $1K in Q1 2014.
  • 89 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2014.

Based on Piershale Financial Group's 13F filing for Q2 2014, filed 17 Jul 2014.